Glenmark Pharma
Glenmark Pharmaceuticals Ltd. (NSE: GLENMARK) is a leading Indian pharmaceutical company with a diversified portfolio across branded formulations, generics, specialty medicines, and active pharmaceutical ingredients (APIs). The company has a strong presence in India, the US, Europe, Latin America, and emerging markets. Glenmark is also investing in respiratory, dermatology, oncology, and innovative drug research, positioning itself for long-term growth.
| Parameter | Rating | Remarks |
|---|---|---|
| NSE Symbol | GLENMARK | Listed on NSE |
| Business Quality | ⭐⭐⭐⭐⭐ | Global pharmaceutical company |
| Revenue Growth | ⭐⭐⭐⭐☆ | Healthy domestic & export growth |
| Profit Growth | ⭐⭐⭐⭐☆ | Improving margins and profitability |
| ROE | ⭐⭐⭐⭐☆ | Strong improvement |
| ROCE | ⭐⭐⭐⭐☆ | Healthy capital efficiency |
| Debt | ⭐⭐⭐⭐☆ | Debt reducing steadily |
| Cash Flow | ⭐⭐⭐⭐⭐ | Strong operating cash flow |
| Promoter Holding | ⭐⭐⭐⭐☆ | Stable promoter ownership |
| Long-Term Outlook | ⭐⭐⭐⭐⭐ | Positive |
Glenmark is among India’s leading branded pharmaceutical companies with a diversified portfolio across chronic and acute therapies.
The company exports generic medicines to regulated markets including the US and Europe, creating diversified revenue streams.
Investments in respiratory, dermatology, oncology, and biologics provide long-term growth opportunities.
Multiple manufacturing facilities approved by global regulators support exports and product quality.
Operations across more than 80 countries reduce dependence on a single market.
🟢 Strong demand for branded formulations in India.
🟢 Improving profitability through better product mix and operational efficiency.
🟢 Expansion of specialty and innovative therapies.
🟢 Continued growth in emerging international markets.
🟢 Healthy balance sheet with improving cash generation.
🟢 Potential benefits from new product launches and regulatory approvals.
🔴 US generic pricing pressure may impact margins.
🔴 Regulatory observations at manufacturing plants could affect exports.
🔴 Currency fluctuations may impact overseas earnings.
🔴 High competition in domestic and international pharmaceutical markets.
🔴 R&D investments may take longer to generate meaningful returns.
Potential Upside Zones
Weakness may emerge if:
Possible downside zones:
| Period | Outlook |
|---|---|
| 1 Year | Bullish |
| 3 Years | Strong Bullish |
| 5 Years | Bullish |
| Base Case | ₹4,000–₹4,800 | Strong Earnings Growth |
| High Bullish Case | ₹6,000–₹7,500 | Exceptional Growth Potential |
Long-Term Rating: ⭐⭐⭐⭐⭐ (Very Bullish)
Glenmark is transitioning from a traditional generics company to an innovation-driven pharmaceutical business with specialty drugs, biologics, and oncology products.
The company secured a major licensing agreement with AbbVie for its innovative oncology asset, providing a substantial upfront payment, milestone opportunities, and future royalty income. It has also expanded its oncology portfolio through new licensing agreements.
Glenmark continues to outperform the Indian pharmaceutical market through new launches, strong branded formulations, and increasing market share.
Expansion across the US, Europe, Latin America, and emerging markets provides diversified long-term growth opportunities.
Investments in respiratory, dermatology, oncology, biologics, and innovative therapies could significantly improve profitability over the next five years.
Glenmark Brands
| Rank | Brand Name | Therapy |
|---|---|---|
| 1 | Ryaltris® | Respiratory |
| 2 | Candid® | Dermatology |
| 3 | Telma® | Cardiovascular |
| 4 | Ascoril® | Respiratory |
| 5 | Klenzit® | Dermatology |
| 6 | Alex® | Respiratory |
| 7 | Momate® | Dermatology |
| 8 | Tacroz® | Dermatology |
| 9 | Supirocin® | Dermatology |
| 10 | Akynzeo®(Commercial) | Oncology |
| 11 | Keto Plus® | Dermatology |
| 12 | Scalpe® | Dermatology |
| 13 | Combiwave® | Respiratory |
| 14 | MISDAPRE® | Respiratory |
| 15 | TEVIMBRA® | Oncology |
| 16 | Brukinsa® | Oncology |
| 17 | Episoft® | Dermatology |
| 18 | Abirapro® | Oncology |
| 19 | Dirnelid®AZ | Respiratory |
| 20 | Nebzmart® | Respiratory |
| 21 | Deriva® | Dermatology |
| 22 | Glenmark Airz® | Respiratory |
ABB India surged over 8% today because investors focused on its long-term growth story rather…
The recent Q1 FY27 earnings release from ICICI Lombard General Insurance Co. Ltd. (NSE: ICICIGI)…
[et_pb_section][et_pb_row][et_pb_column type="4_4"][et_pb_text] Tata Power – Building India's Energy Future Tata Power Ltd. is one of…
The 9:00 AM–9:08 AM pre-open session can provide useful clues about market sentiment, but it…
🟢 Bullish Analyst Opinions 1. India's Largest Private Thermal Power Producer Adani Power continues to…
Overall Analyst Consensus Consensus Rating: Buy Analysts Covering: 31 Buy: 22 Hold: 8 Sell: 1…